Tags

Type your tag names separated by a space and hit enter

Azithromycin in lower respiratory tract infections.
Scand J Infect Dis Suppl. 1992; 83:26-33.SJ

Abstract

Azithromycin is a new azalide antimicrobial agent which has a broad spectrum of activity against common lower respiratory tract pathogens including pneumococci, staphylococci, Legionella species, Mycoplasma and Chlamydia species. In particular, it is more active against Haemophilus influenzae than other macrolides. In comparison to other new macrolides, azithromycin achieves higher tissue and intracellular concentrations and these concentrations are sustained for several days after dosing due to a long elimination half-life. The efficacy of azithromycin against lower respiratory tract infections has been proven in several clinical studies. Once-daily dosing with azithromycin, over a 3- or 5- day period was as effective as a 10-day course of other commonly used antibiotics such as amoxycillin/clavulanic acid, erythromycin or cefaclor in lower respiratory tract infections. Azithromycin short-course therapy may offer an advantage in terms of patient compliance and the duration of treatment.

Authors+Show Affiliations

Department of Chest and Infectious Diseases, City Hospital Zehlendorf Heckeshorn, Berlin, Germany.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1336893

Citation

Lode, H, and T Schaberg. "Azithromycin in Lower Respiratory Tract Infections." Scandinavian Journal of Infectious Diseases. Supplementum, vol. 83, 1992, pp. 26-33.
Lode H, Schaberg T. Azithromycin in lower respiratory tract infections. Scand J Infect Dis Suppl. 1992;83:26-33.
Lode, H., & Schaberg, T. (1992). Azithromycin in lower respiratory tract infections. Scandinavian Journal of Infectious Diseases. Supplementum, 83, 26-33.
Lode H, Schaberg T. Azithromycin in Lower Respiratory Tract Infections. Scand J Infect Dis Suppl. 1992;83:26-33. PubMed PMID: 1336893.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Azithromycin in lower respiratory tract infections. AU - Lode,H, AU - Schaberg,T, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 26 EP - 33 JF - Scandinavian journal of infectious diseases. Supplementum JO - Scand J Infect Dis Suppl VL - 83 N2 - Azithromycin is a new azalide antimicrobial agent which has a broad spectrum of activity against common lower respiratory tract pathogens including pneumococci, staphylococci, Legionella species, Mycoplasma and Chlamydia species. In particular, it is more active against Haemophilus influenzae than other macrolides. In comparison to other new macrolides, azithromycin achieves higher tissue and intracellular concentrations and these concentrations are sustained for several days after dosing due to a long elimination half-life. The efficacy of azithromycin against lower respiratory tract infections has been proven in several clinical studies. Once-daily dosing with azithromycin, over a 3- or 5- day period was as effective as a 10-day course of other commonly used antibiotics such as amoxycillin/clavulanic acid, erythromycin or cefaclor in lower respiratory tract infections. Azithromycin short-course therapy may offer an advantage in terms of patient compliance and the duration of treatment. SN - 0300-8878 UR - https://www.unboundmedicine.com/medline/citation/1336893/Azithromycin_in_lower_respiratory_tract_infections_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.